13 November 2018
Lit-Control® is the world's first digital therapeutics solution that allows the most common urological diseases to be prevented and treated effectively from home while also improving patients' adherence to the treatment.
“We're excited to work with Exeltis to expand the use of Lit-Control® and provide a response to the uncovered medical needs in the area of urology thanks to the constant work with the scientific-medical community and patients” says Rosendo ...
12 November 2018
iVascular, a CataloniaBio & HealthTech member, has acquired 10% of the shares of the American start-up NaviGate Cardiac Structures for €8,7 million. With this purchase, iVascular becomes part of the Board of Directors of the Navigate.
The agreement between both companies, contemplates the joint development of a new product: the tricuspid valve with percutaneous access. Clinical studies are currently underway in the United States and Europe to analyze the efficacy and safety of this valve, that is estimated to be ready for clinical application by 2020.
iVascular has its headquarters in Sant Vicenç dels Horts (Barcelona).
6 November 2018
Laboratorios Rubió ha invertit 4 milions d'euros a la fàbrica de Castellbisbal (Barcelona) amb la mirada posada als Estats Units, segons informa La Vanguardia. La farmacèutica dirigida per Pelayo Rubió produeix 6 milions d'unitats de fàrmacs anuals.
"Esperem començar a comercialitzar els nostres productes al mercat nord-americà el 2020" ha declarat Pelayo Rubió .L'empresa va facturar 30,7 milions d'euros el 2017, un 20% més que el 2016, i té presència a 47 països.
Recomanem la vídeoentrevista de CataloniaBio & HealthTech a Pelayo Rubió:
30 October 2018
The biomedical industry entrepreneur Antonio Parente has joined the Specipig board of directors as an independent member. Parente will combine this position with his roles on the governing bodies of GP Pharm and BCN Peptides.
Parente's experience will be key in the Catalan company's international consolidation phase, five years after it was founded. Specipig is the only company in the whole of Europe to offer the whole process from pig breeding to CRO services for biomedical research. 80% of its turnover is already from other countries.
Dr Parente was a founder of CataloniaBio, and in 2010 and 2014 was president ...
26 October 2018
Aelix Therapeutics, a CataloniaBio & HealthTech member, and Gilead Sciences Inc. have entered into collaboration to jointly evaluate proprietary research products in a strategic clinical study aimed at achieving a functional cure for HIV.
The collaboration will allow them to conduct clinical study Aelix-003 to assess the safety, tolerability, immunogenicity and efficacy of a regimen of the Aelix HTI T-cell vaccine and the Gilead Toll-Like Receptor 7 agonist vesatolimod in HIV-infected individuals already on antiretroviral therapy. The Aelix-003 trial is expected to begin in early 2019.
Aelix Therapeutics has its headquarters at the Barcelona Science Park.
Photo: Dr ...
25 October 2018
The University of Barcelona Production and validation centre of advanced therapies (Creatio), a member of CataloniaBio & HealthTech, is coordinating the Advanced Stem Cell Technologies for Neurology (ASCTN-Training) programme that has been launched with €3.8 million in funding from the European Commission Horizon 2020 programme.
ASCTN-Training brings together eleven public and private institutions, providing training in interdisciplinary research and high-level transversal skills for fourteen young researchers to develop cell therapies applied to neuronal disorders.
It should be noted that another Catalan entity, the Institute for Bioengineering of Catalonia (IBEC), is also participating.
Additionally, this week Creatio has been accredited ...
25 October 2018
Mabia, a Barcelona based registered financial analysis firm with a long track record in the Spanish Alternative Stock Market (MAB), has been selected as Spanish equity research partner for Euronext’s Trade & Leverage programme, part of its European Tech SME initiative to assist tech companies in developing their business on a greater scale through capital markets.
Jordi Rovira, CEO of Mabia, says "we are very proud to have been selected as Spanish equity research partner for German, Italian, Spanish and Swiss tech companies newly listed on Euronext".
Photo: Jordi Rovira - IMB Grup
19 October 2018
Twenty biomedical research projects and nearly thirty business development experts and mentors participated in the fourth edition of Health & Bio Team Dating in Barcelona, the only business speed-dating event in the sector hold on 17th October in Barcelona. This edition of Health & Bio Team Dating hosted 90 speed dates, with scientists presenting their research to professionals with business experience interested in growing these projects as mentors, entrepreneurs or business developers.
12 October 2018
Bionure, a biotech company specialized in neuroprotection member of CataloniaBio & HealthTech, announces the appointment of Dr. Laurent Nguyen as the new CEO and strengthens its scientific team with the arrival of Dr. Amit Bar-Or, a multiple sclerosis specialist.
Nguyen is doctor in Medicine and has a solid experience in the pharmaceutical industry at Hoechst-Roussel, Merck, F. Hoffmann-La Roche and Pierre Fabre. He then moved to the biotech sector where he became CEO of a French academic spin-off that he developed into a publicly traded clinical biotech company.
The ongoing Phase I clinical trial of its neuroprotective and remyelinating compound ...
11 October 2018
Alta Life Sciences, the fund led by Guy Nohra, Montserrat Vendrell, Miguel Valls and Scott Moonly and a CataloniaBio & HealthTech member, has led a €3-million round of investment in Mediktor. The round also included Dutch fund Castel Capital and French Naos Capital Partners.
Mediktor is a symptom assessment software launched as a free app in 2014. Over this time, it has done more than 2 million evaluations of symptoms in 150 countries and created a database that can recognise roughly 750 diseases, covering 90% of the cases seen in emergency and primary care. Recently, Mediktor has collaborated with Hospital ...